Anthropic has acquired stealth biotech AI startup Coefficient Bio in a stock deal reportedly worth around $400 million, as first reported by The Information and Eric Newcomer and later confirmed by sources close to the transaction, who did not disclose the exact amount. The acquisition aligns with Anthropic’s broader expansion into healthcare and life sciences, following the October launch of “Claude for Life Sciences,” a tool designed to help scientific researchers accelerate discoveries in areas such as drug development and biological analysis.
Coefficient Bio, founded just eight months ago by Samuel Stanton and Nathan C. Frey after their experience in computational drug discovery at Genentech’s Prescient Design, focused on using AI to make drug discovery and other biological research more efficient. Its small team of roughly 10 people is expected to join Anthropic’s health and life sciences group, strengthening Anthropic’s internal expertise at the intersection of AI and biotech.
With this move, Anthropic not only gains specialized talent and early-stage technology, but also signals an intention to compete more directly in the use of advanced AI models to solve complex biological problems, a field that is attracting growing interest from both startups and large technology companies. The deal illustrates how AI companies are increasingly investing in domain-specific applications, especially in sectors like biotechnology, where the combination of data, computation, and scientific knowledge can unlock new commercial and research opportunities.
Reference
Davis, D.-M. (2026, April 3). Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports. TechCrunch. https://techcrunch.com/2026/04/03/anthropic-buys-biotech-startup-coefficient-bio-in-400m-deal-reports/